Argos Therapeutics (ARGS) Announces Quarterly Earnings, Misses Estimates By $0.01 EPS
Argos Therapeutics (NASDAQ:ARGS) released its earnings data on Wednesday. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by $0.01, AR Network reports. The company had revenue of $1.26 million for the quarter, compared to the consensus estimate of $1.27 million.
Argos Therapeutics (NASDAQ:ARGS) traded up 1.66% during mid-day trading on Wednesday, hitting $6.11. The stock had a trading volume of 13,103 shares. Argos Therapeutics has a 52 week low of $5.611 and a 52 week high of $13.74. The stock has a 50-day moving average of $6.7 and a 200-day moving average of $8.38. The company’s market cap is $120.1 million.
Argos Therapeutics Inc is a United States-based biopharmaceutical company. The company focused on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis technology platform.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.